ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Smoking Cessation After Diagnosis of Kidney Cancer Is Associated With Reduced Risk of Mortality and Cancer Progression: A Prospective Cohort Study.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Effect of tobacco avoidance on the incidence of non-hereditary renal cell carcinoma in patients over 18 years of age: systematic review and meta-analysis.International urology and nephrology · 2026Pooled it
- Impact of Lifestyle Modifications on Cancer Mortality: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Economic and health impact of integrating smoking cessation services into NHS cancer care pathways in England: a modelling study.The Lancet regional health. Europe · 2026Article
- Neurogenic Small Molecules Reverse miR-342-3p-Mediated Tumorigenesis in Renal Cell Carcinoma.World journal of oncology · 2026Article
- The preventable burden of tobacco-attributable cancer incidence in Catalonia (Spain) in 2024: a Bayesian approach.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Survival among US adults with post-cancer-diagnosis cigarette smoking cessation.Cancer causes & control : CCC · 2026Article
- Prognostic role of smoking in metastatic renal cell carcinoma in real-world data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC).Scientific reports · 2026Article
- Sustainment of Tobacco Use Treatment Programs Across National Cancer Institute-Designated Cancer Centers.Cancer medicine · 2025Article
- The impact of smoking on nivolumab outcomes in renal cell carcinoma: real-world data from the Turkish Oncology Group Kidney Cancer Consortium.The oncologist · 2025Article
- Competing risk of death in patients with low, intermediate and high risk of recurrence after radical surgery for clear cell renal cell carcinoma.BJUI compass · 2025Article
- Treating tobacco dependency in cancer care: essential, cost-effective, and feasible, yet overlooked.British journal of cancer · 2025Article
- The global burden of bladder, kidney, and prostate cancers attributable to smoking from 1990 to 2021 and projections for the next two decades: A cross-sectional study.Tobacco induced diseases · 2025Article
- Androgen Receptor and Non-Coding RNAs' Interaction in Renal Cell Carcinoma.Non-coding RNA · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
purposeTo investigate whether postdiagnosis smoking cessation may affect the risk of death and disease progression in patients with renal cell carcinoma (RCC) who smoked at the time of diagnosis.
methodsTwo hundred twelve patients with primary RCC were recruited between 2007 and 2016 from the Urological Department in N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia. Upon enrollment, a structured questionnaire was completed, and the patients were followed annually through 2020 to repeatedly assess their smoking status and disease progression. Survival probabilities and hazards for all-cause and cancer-specific mortality and disease progression were investigated using extended the Kaplan-Meier method, time-dependent Cox proportional hazards regression, and Fine-Gray competing-risk models.
resultsPatients were followed for a median of 8.2 years. During this time, 110 cases of disease progression, 100 total deaths, and 77 cancer-specific deaths were recorded. Eighty-four patients (40%) quit smoking after diagnosis. The total person-years at risk for this analysis were 748.2 for continuing smoking and 611.2 for quitting smoking periods. At 5 years of follow-up, both overall survival (85%
conclusionQuitting smoking after RCC diagnosis may significantly improve survival and reduce the risk of disease progression and cancer mortality among patients who smoke.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.